ALGN vs NBIX: fair value comparison
Align Technology, Inc. and Neurocrine Biosciences, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ALGN currently sits closer to the top of our discount ranking. NBIX carries the stronger quality grade.
| ALGN | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $150.82 | $156.76 |
| 12-month range | $137.88–$189.02 | $131.78–$167.77 |
| Sector rank | #12 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ALGN fair value analysis · NBIX fair value analysis